Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06676774 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls

Study acronym: OxyMOTION
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2025 to May 16, 2025
    • Site details revised
    v3
  2. Start date: Jan 10, 2025 to Mar 2025
    • Primary and study completion dates: Jan 31, 2027 to Feb 2027
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to investigate the potential beneficial effects of intranasal oxytocin compared to placebo on emotion recognition and acute psychosocial stress in patients with arginine vasopressin deficiency compared to matched healthy controls.
Trial Details
NCT Number NCT06676774
Lead Sponsor University Hospital, Basel, Switzerland
Conditions
(from sponsor)		 Arginine Vasopressin Deficiency, Diabetes Insipidus
Related terms Diabetes Insipidus, Diabetes Insipidus, Neurogenic
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov